Partner Dan Shores will speak on "Navigating the ADC Patent Landscape: Strategic Approaches to Taking Advantage of Key ADC Patent Expirations & Building ADC Patent Assets With & Without Traditional Payloads" at the 5th Annual Novel Conjugates Summit taking place March 17-19, 2026, in Boston, Massachusetts. Dan's session will take place on the second day of the conference, March 19.
Dan's session will analyze the implications of traditional payload patent expiration on ADC development strategy; review opportunities for medicinal chemistry modifications to create novel IP around off-patent payloads; and explore strategic approaches to protecting novel ADC candidates and evaluating potential candidates against the patent landscape.
Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications. The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has, and the directions the space is heading. Attendees will gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from established pharma leaders to the newest biotech entrants.
To learn more, and to register, please visit the event website.
